Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Marginal zone lymphomas (MZL) are indolent lymphomas that may undergo transformation into aggressive lymphomas, most frequently diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine is an antibody–drug conjugate used in the treatment of relapsed/refractory large B-cell lymphomas. Here we present the clinical case of a patient with nodal involvement by transformed DLBCL and concomitant bone marrow involvement by indolent lymphoma, successfully treated with short-term administration of loncastuximab, who subsequently developed treatment-related bone marrow aplasia.
